Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.46 |
| ▸ | SCN1A | P35498 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2625918 | 1.00 | SCN9A (0.52) | SCN9AROCK2KMT2ASCN8ASCN1A | |
| SCHEMBL2626065 | 0.95 | KMT2A (0.52) | SCN9AROCK2KMT2ASCN8ASCN1A | |
| SCHEMBL1576703 | 0.95 | KMT2A (0.52) | SCN9AROCK2KMT2ASCN8ASCN1A | |
| SCHEMBL1576529 | 0.95 | KMT2A (0.52) | SCN9AROCK2KMT2ASCN8ASCN1A | |
| SCHEMBL2626690 | 0.89 | SCN9A (0.47) | SCN9AKMT2ASCN8AALDH1A1MEN1 | |
| SCHEMBL2626006 | 0.89 | SCN9A (0.47) | SCN9AKMT2ASCN8AALDH1A1MEN1 | |
| SCHEMBL10310764 | 0.89 | SCN9A (0.49) | SCN9AKMT2ASCN5A | |
| SCHEMBL2626688 | 0.89 | SCN9A (0.49) | SCN9AKMT2ASCN5A | |
| SCHEMBL1576275 | 0.89 | SCN9A (0.52) | SCN9AKMT2ASCN8ASCN1ALMNA | |
| SCHEMBL1576868 | 0.89 | SCN9A (0.52) | SCN9AKMT2ASCN8ASCN1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586589-B2 | Piperidine and piperazine phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-7799822-B2 | Phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799822-B2 | Phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | SCN9A 125/4885ROCK2 3404/4885KMT2A 2855/4885 |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | SCN9A 104/4885ROCK2 4204/4885KMT2A 1452/4885 |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | TRPV1, TRPV5, TRPA1 | SCN9A 131/4885ROCK2 3604/4885KMT2A 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.